Effects of sc Administration of Recombinant Human Insulin-Like Growth Factor I (IGF-I) on Normal Human Subjects

抄録

Recombinant human insulin-like growth factor I (IGF-I) was administered subcutaneously to each of 5 normal human subjects at doses of 0mg/kg (control), 0.06mg/kg, or 0.12mg/kg successively at one week intervals. After 0.06mg/kg or 0.12mg/kg IGF-I injections, plasma IGF-I levels increased from 185±17ng/ml (Mean±SEM) to maximal levels of 396±21ng/ml at 3 hours and from 169±14ng/ml to 480±27ng/ml at 4 hours, respectively. These two peak values were statistically different (p<0.05). After 0.06mg/kg and 0.12 mg/kg IGF-I administration, blood glucose levels decreased from 85±2mg/dl to minimal levels of 73±3mg/dl at 3 hours and from 83±1mg/dl to 50±4 mg/dl at 2 hours, respectively. These two minimal values were statistically different (p<0.001).
Serum insulin and C-peptide levels were decreased in a dose dependent manner after IGF-I administration. There were no changes between blood urea nitrogen levels before and 4 hours after IGF-I administration. The urinary GH concentration decreased after 0.06mg/kg IGF-I administration, but increased and maintained normal values after 0.12mg/kg IGF-I administration.